FindTrial
Sign In

ILT-101

DRUG2 trials

Sponsors

Iltoo Pharma, Assistance Publique - Hôpitaux de Paris

Conditions

Systemic Lupus ErythematosusThe Immune Dysregulation Polyendocrinopathy Enteropathy X-linked Syndrome is a Primary Immunodeficiency Caused by Pathogenic Variants in Forkhead Box Protein 3

Phase 1

Study Evaluating a Gene Therapy for IPEX Syndrome Through the Expression of FOXP3 on Deficient T Cells to Produce Tregs-like.
Not yet recruitingNCT07697118
Assistance Publique - Hôpitaux de ParisThe Immune Dysregulation Polyendocrinopathy Enteropathy X-linked Syndrome is a Primary Immunodeficiency Caused by Pathogenic Variants in Forkhead Box Protein 3
Start: 2026-09-01End: 2029-01-01Target: 5Updated: 2026-07-13

Phase 2

ILT-101 in Patients With Active Moderate to Severe Systemic Lupus Erythematosus (SLE)
CompletedNCT02955615
Iltoo PharmaSystemic Lupus Erythematosus
Start: 2017-01-18End: 2019-02-11Updated: 2019-03-05

Related Papers

LOW-DOSE INTERLEUKIN-2 THERAPY IN ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS (LUPIL-2): A MULTICENTER, DOUBLE-BLIND, RANDOMIZED AND PLACEBO-CONTROLLED PHASE 2 TRIAL
The Journal of Rheumatology2025-05-20
S11.3 Low-dose interleukin-2 therapy in active systemic lupus erythematosus (lupil-2): a multi-center, double-blind, randomized and placebo-controlled phase 2 trial
2022-09-271 citations
Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial.
2022-08-1675 citations